Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
and in a phase 1 study achieved clinically significant body weight reductions over 12 weeks in people with obesity and without diabetes, according to Amgen. The drug was given as a subcutaneous ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Amgen (AMGN) gains traction with a 26% YTD rise, strong earnings, and a robust dividend. Analysts signal growth potential ...
The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...
Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...
Zacks Investment Research on MSN2d
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback